Carcinoma, Colorectal Clinical Trial
Official title:
A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.
Status | Completed |
Enrollment | 15 |
Est. completion date | December 2015 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically-confirmed, advanced/metastatic colorectal carcinoma - Failed both oxaliplatin and irinotecan based regimens for advanced/metastatic disease (if tumor advanced either immediately or within 3 months of the end of treatment) - Resistance to Erbitux: patients with Ras mutations, or for whom Erbitux has failed (if tumor advanced either immediately or within 3 months of the end of treatment, or there is no response to Erbitux therapy due to a lack of expression of EGFR (epidermal growth factor)) - Karnofsky Performance Score (KPS) = 70 - Age =18 years - Laboratory Safety: WBC = 3,500 cells/mm3 and = 50,000 cells/mm3, ANC = 1,500 cells/mm3, Hemoglobin = 10 g/dL (transfusion allowed), Platelet count = 100,000 plts/mm3,Total bilirubin = 1.5 X ULN, INR = 1.5, AST, ALT = 2.5x ULN (in case of liver metastasis: AST,ALT =5.0 x ULN) - Serum chemistries within normal limits (WNL) or Grade 1 (excluding alkaline phosphatase) - If patients are diabetic, a fasting glucose must be done and patients must be > 160 mg/dL. - Patients who, if they are sexually active, are willing and able to refrain from sexual activity for 3 weeks following JX-594 administration. Patients who are willing and able to use a permitted contraceptive for 3 months after the final administration of JX-594. Exclusion Criteria: - Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids) - Known myeloproliferative disorders requiring systemic therapy - History of exfoliative skin condition (e.g. eczema or ectopic dermatitis) requiring systemic therapy - History of acquiring opportunistic infections. - Tumor(s) invading a major vascular structure (e.g. carotid artery) - Tumor(s) in location that would potentially result in significant clinical adverse effects if post-treatment tumor swelling were to occur - Clinically uncontrolled and/or rapidly accumulating ascites, pericardial and/or pleural effusions - History of severe or unstable cardiac disease - Current, known CNS malignancy (history of completely resected or irradiated brain metastases by WBRT or stereotactic radiosurgery allowed) - Administered anti-cancer therapy within 4 weeks prior to first treatment (6 weeks in case of mitomycin C or nitrosoureas) - Use of anti-viral, anti-platelet, or anti-coagulation medication [Patients who discontinue such medications within 7 days prior to first treatment may be eligible for this study.] Low dose aspirin (approximately 81 mg) allowed. - Pulse oximetry O2 saturation <90% Pulse oximetry O2 saturation <90% at rest - Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination - Pregnant or nursing - Household contact exclusions: - Women who are pregnant or nursing an infant - Children < 5 years old - People with skin disease (e.g. eczema, atopic dermatitis, and related diseases - Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologic malignancies) |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Jennerex Biotherapeutics | Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by biweekly intravenous (IV) infusion | Any of the following treatment related adverse events: Grade 4 toxicity, Grade 3 hematologic toxicity for > 5 days, Grade 3 non-hematologic toxicities persisting for > 7 days except for flu-like symptoms that respond to standard therapies. | DLT evaluations through 14 days following last JX-594 treatment | Yes |
Primary | Determine the safety of JX-594 administered by biweekly IV infusion | Adverse events will be collected and assessed to assess safety and tolerability through 28 days after last dose of JX-594 (or until all events considered probably or possibly related to JX-594 have resolved, stabilized, or returned to baseline status). | Safety evaluations through 28 days after last dose of JX-594 | Yes |
Secondary | Determine the pharmacokinetics, pharmacodynamics and immune response activity of JX-594 | Change over time in viral genomes, infectious units, GM-CSF concentration, peripheral white blood cell counts, plasma cytokine measurements, and neutralizing antibodies to JX-594 in blood and/or serum. | Blood samples collected at assigned time points from baseline through Week 8 | No |
Secondary | Determine the anti-tumoral response of JX-594 | Tumor response (Stable, partial, complete, progression) by standard RECIST on CT/MRI. Decrease in tumor blood marker. | Disease control and response assessment at Week 8 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04291755 -
Development and Analysis of a Stool Bank for Cancer Patients
|
||
Recruiting |
NCT04699188 -
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 |